

Ajardy

Empagliflozin INN



Composition

Ajardy 10: Each film coated tablet contains Empagliflozin INN 10 mg.

Ajardy 25: Each film coated tablet contains Empagliflozin INN 25 mg.

Pharmacology

Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the predominant transporter responsible for reabsorption of glucose from kidney back into the circulation. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Indications

Empagliflozin is indicated:

- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Dosage and Administration

The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.

Contraindications

Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.

Warnings and Precautions

Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not be initiated in patients with an eGFR less than 45 mL/min/1.73m². No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73m².

The risk of necrotizing fasciitis of the perineum/Fournier's gangrene is very rare. Consult with doctor immediately if you experience any symptoms of tenderness, redness or swelling of the genitals or the area from the genitals back to the rectum and have a fever above 100.4 °F.

Adverse Effects

The most common adverse reactions associated with Empagliflozin are urinary tract infections and female genital mycotic infections. Others common side effects include dehydration, hypotension, weakness, dizziness and increase thirstiness.

Interactions

Diuretics: Co-administration of Empagliflozin with diuretics resulted in increased urine volume.

Insulin or Insulin Secretagogues: Co-administration of Empagliflozin with insulin or insulin secretagogues increases the risk of hyperglycemia.

Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative method to monitor glycemic control.

Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

Use in Pregnancy & Lactation

There are no adequate and well controlled studies of Empagliflozin in pregnant women. Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empagliflozin is excreted in human milk. It is not recommended when breastfeeding.

Overdosage

In the event of an overdose with Empagliflozin, Employ the usual supportive measures as dictated by the patient's clinical status (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment). Removal of empagliflozin by hemodialysis has not been studied.

Storage Conditions

Do not store above 25°C. Protect from light. Keep out of the reach of children.

Packaging:

Ajardy 10: Each box contains 3X10's tablets in blister pack.

Ajardy 25: Each box contains 1X10's tablets in blister pack.

Manufactured by



Ziska Pharmaceuticals Ltd.

Kaliakoir, Gazipur, Bangladesh